Raltegravir is the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor; it targets the strand transfer step of HIV-1 integration. Clinical trials have demonstrated that raltegravir-containing regimens have potent antiretroviral activity and are well tolerated in HIV-1–infected individuals. In antiretroviral treatment–experienced persons with drug-resistant HIV infection, raltegravir-containing treatment with an optimized background regimen was superior to an optimized background regimen alone. In treatment-naive persons, raltegravir was not inferior to efavirenz when the drugs were administered with tenofovir and lamivudine or emtricitabine. Raltegravir is metabolized by glucuronidation, not hepatically; thus, the potential for drug-drug interactions is decreased. Drug resistance, conferred by substitutions in the gene coding for the HIV-1 integrase enzyme, develops relatively frequently after virologic failure. As an antiretroviral drug with a novel mechanism of action, raltegravir is an important advancement in HIV-1 treatment options.
Key words of the product are Raltegravir Pharm Hiv Integrase Inhibitor,Raltegravir Medicine 99% Integrase,
Hiv Integrase Isentress Dolutegravir Mk 0518
Chemical Name: BENZYL [1-[4-[[(4-FLUOROBENZYL)AMINO]CARBONYL]-5-HYDROXY-1-METHYL-6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL]-1-METHYLETHYL]CARBAMATE
Molecular Formula: C24H25FN4O5
Formula Weight: 468.48
CAS No.: 518048-02-7
Looking for ideal Raltegravir Pharm Hiv Integrase Inhibitor Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the Raltegravir Medicine 99% Integrase are quality guaranteed. We are China Origin Factory of Hiv Integrase Isentress Dolutegravir Mk 0518. If you have any question, please feel free to contact us.
Product Categories : Intermediates > Other Intermediates